PLP3 Antibody
Description
Definition and Biological Relevance
PLP3 antibodies target phospholipid phosphatase 3 (PLPP3), also known as PPAP2B or LPP3, a 35.1 kDa protein localized to cell membranes. PLPP3 regulates lipid phosphate metabolism, including hydrolysis of phosphatidic acid and lysophosphatidic acid, and is essential for:
The protein is ubiquitously expressed across tissues and conserved in mammals, reptiles, and zebrafish .
Applications in Research
PLP3 antibodies are utilized in multiple experimental contexts:
Association with Multiple Sclerosis
-
Anti-PLP antibodies targeting residues 181–230 correlate with MS severity in HLA-compatible patients. Elevated levels are linked to increased demyelination and disability progression .
-
Antibodies like P7.6A5 (epitope 178–191) and F4.8A5 (epitope 200–219) bind natively folded PLP on oligodendrocytes, suggesting a direct role in autoimmune attacks .
Challenges in Antibody Validation
-
Specificity Issues: Non-recombinant PLP3 antibodies often lack adequate validation, leading to false positives. Third-party testing is recommended to confirm target recognition .
-
Batch Variability: Polyclonal antibodies exhibit lot-to-lot inconsistency, unlike recombinant alternatives .
Future Directions
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Target Background
Q&A
PLP3 Antibody: Frequently Asked Questions for Academic Researchers
Advanced Research Questions
How can researchers resolve contradictory data on PLP3 localization across studies?
-
Strategies:
-
Contextual analysis: Assess differences in cell lines, fixation methods, or antibody batches (e.g., HEK293 vs. CHO expression systems may yield varying glycosylation patterns) .
-
Orthogonal validation: Combine IF with subcellular fractionation followed by Western blot (e.g., nuclear/cytoplasmic separation) .
-
Epitope mapping: Use truncated PLP3 constructs to identify antibody-binding regions and assess cross-reactivity .
-
What experimental design considerations are critical for PLP3 antibody-based therapeutic studies?
-
Key parameters:
-
Affinity vs. specificity: Prioritize antibodies with ≤1 nM KD (surface plasmon resonance) and >100-fold selectivity over homologs .
-
In vivo models: Use PLP3-transgenic mice to evaluate target engagement and off-tumor toxicity .
-
Dose optimization: Apply a factorial DOE (Design of Experiments) to assess variables like pH, temperature, and antibody concentration .
-
Methodological Comparisons
Table 1: PLP3 Antibody Validation Techniques
Table 2: Expression Systems for Recombinant PLP3 Antibodies
| System | Yield (mg/L) | Glycosylation Profile | Ideal Use Case |
|---|---|---|---|
| HEK293 | 50-100 | Human-like | Early-stage screening |
| CHO | 200-500 | Low fucosylation | Therapeutic development |
Addressing Technical Challenges
How can cross-reactivity with PLP family members be minimized?
-
Solution:
What computational tools aid in predicting PLP3-antibody interactions?
-
Tools:
Data Interpretation
How should researchers interpret low signal-to-noise ratios in PLP3 IHC?
-
Troubleshooting steps:
What statistical approaches are recommended for PLP3 expression analysis in heterogeneous samples?
-
Recommendations:
